Carr, RB, Shrewsbury, K. ( 2007) Hyperammonemia due to valproic acid in the psychiatric setting. Am J Psychiatry164: 1020-1027.
2.
Chen, KC, Yang, YK, Chen, PS, Yeh, TL, Yang, MJ ( 2003) Two case studies of hypothermia induced by an increased dosage of zotepine in a combination therapy. Psychiatry Clin Neurosci57: 369-371.
3.
Chicharro, AV, de Marinis, AJ, Kanner, AM ( 2007) The measurement of ammonia blood levels in patients taking valproic acid: looking for problems where they do not exist. Epilepsy Behav11: 361-366.
4.
Dealberto, MJ ( 2007) Valproate-induced hyperammonaemic encephalopathy: review of 14 cases in the psychiatric setting. Int Clin Psychopharmacol22: 330-337.
5.
Huang, YT, Chien, Y., Yeh, HY, Lin, SJ, Lu, FL, Chou, SP, et al. (2003) Phenotype and genotype analyses of ornithine transcarbamylase deficiency in Taiwanese. J Formos Med Assoc102: 851-856.
6.
Perucca, E. ( 2002) Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs16: 695-714.
7.
Prakash, A., Lamb, HM ( 1998) Zotepine: A Review of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Efficacy in the Management of Schizophrenia. CNS Drugs9: 153-175.
8.
Raja, M., Azzoni, A. ( 2002) Valproate-induced hyperammonaemia. J Clin Psychopharmacol22: 631-633.
9.
Segura-Bruna, N., Rodriguez-Campello, A., Puente, V., Roquer, J. ( 2006) Valproate-induced hyperammonemic encephalopathy. Acta Neurol Scand114: 1-7.
10.
Tuchman, M., Plante, RJ ( 1995) Mutations and polymorphisms in the human ornithine transcarbamylase gene: mutation update addendum. Hum Mutat5: 293-295.
